Catabasis and Bill & Melinda Gates Medical Research Institute to Study CAT-5571 in Drug-Sensitive and Drug-Resistant Tuberculosis

BOSTON–(BUSINESS WIRE)–Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today it entered into an agreement with the Bill & Melinda Gates Medical Research Institute (Gates MRI), a non-profit biotechnology organization, to assess CAT-5571 as a potential oral therapy to promote autophagy and clear persistent lung infections in patients with both drug-sensitive and drug-resistant tuberculosis (TB). Catabasis granted Gates MRI a non-exclusive license to CAT-5571, and will furnish samples of CAT-5571 to conduct this preclinical collaboration research program.

Mycobacterium tuberculosis (Mtb) is known to cause TB. CAT-5571 will be studied alone and in combination with the standard of care regimen in cell and animal models of Mtb infection to determine the potential for CAT-5571 to induce autophagy and encourage Mtb elimination as well as to assess its contribution to TB drug regimens and durations.

In previous preclinical studies, CAT-5571 was shown to restore autophagy in mouse and human cells with the delta508-CFTR mutation and promote the clearance of bacteria, including Mycobacterium abscessus, from these cells. Evidence suggests that autophagy plays a crucial role in antimycobacterial resistance in TB by acting as an alternative mechanism to control Mtb infection in macrophages, as well as to defend and counteract Mtb evasion strategies.

“We are thrilled to work with Gates MRI to expand our understanding of CAT-5571,” said Andrew Nichols, Ph.D., Chief Scientific Officer of Catabasis. “We look forward to learning more about how autophagy could potentially benefit communities with tuberculosis. We hope that a new treatment option may someday benefit those affected, especially those with TB resistant to current treatments.”

About Catabasis

At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our lead program is edasalonexent, an NF-kB inhibitor in Phase 3 development for the treatment of Duchenne muscular dystrophy. For more information on edasalonexent and our Phase 3 PolarisDMD trial, please visit www.catabasis.com.

Check Also

Aimmune Agrees to be Acquired by Nestlé Health Science for $2 Billion

BRISBANE, Calif.–(BUSINESS WIRE)–Aug. 31, 2020– Aimmune Therapeutics Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments …